ABK Biomedical Inc., a Halifax based medical device company, has issued the following press release:
ABK Biomedical Attracts World Leaders to Clinical Advisory Board
HALIFAX, Canada; October 15, 2014 - ABK Biomedical Inc., a Halifax based medical device company, today announced the appointment of three leading experts in interventional radiology to its Clinical Advisory Board: Dr. Scott Goodwin, Dr. Jim Spies and Dr. Bob Lewandowski.
"We are thrilled to have these pioneers in uterine fibroid embolization and interventional oncology on our team of clinical advisors," said Dr. Bob Abraham, chief executive officer of ABK Biomedical. “The experience of these world leaders is going to be invaluable as we move OccluSystem into clinical trials and continue to expand our pipeline of novel radiopaque embolic therapies.”
Dr. Scott Goodwin, incoming Chair of ABK Biomedical’s clinical advisory board stated, “Minimally invasive, image-guided embolic therapies are becoming the patient's first choice for treatment of their uterine fibroids. ABK Biomedical’s innovations in this area make this a very exciting opportunity to guide their efforts, together with the expertise of Dr. Spies and Dr. Lewandowski.”
Dr. Goodwin is an interventional radiologist, best known for introducing uterine artery embolization for the treatment of uterine fibroids (UAE) in North America. He is Chief of Radiology at UC Irvine Medical Center and also performs chemoembolization for liver cancer.
Dr. Goodwin is the Hasso Brothers Chair of the Department of Radiological Sciences at University of California, Irvine Medical School. He has repeatedly been listed among the nation's Best Doctors in America® for Radiology, and is regarded as one of the top 10 researchers in uterine fibroids. Dr. Goodwin completed his M.D. at Harvard University, internship at Washington University, followed by his residency and fellowship at UCLA.
Dr. Jim Spies leads the Georgetown Uterine Fibroid Embolization Program, one of the largest and most experienced in the United States. Dr. Spies has been a principal investigator in five funded research trials, including the FIBROID Registry, a study of 3,000 women. He is Chair of the Radiology Department at MedStar Georgetown University hospital, Professor of Radiology at Georgetown University Medical Center and has published extensively on uterine artery embolization. He completed his M.D. at Georgetown University, residency at University of California, San Francisco, and fellowship in interventional radiology at New York University.
Dr. Bob Lewandowski is an Associate Professor of Radiology and Director of Interventional Oncology at the Northwestern University Feinberg School of Medicine in Chicago. He has published extensively on chemoembolization and radioembolization to treat liver cancer and is a world authority in interventional radio-oncology. A leading researcher, Dr. Lewandowski is involved with both pre-clinical and clinical studies in Interventional Oncology. Dr. Lewandowski received his M.D. from Michigan State University, completed residency at William Beaumont Hospital and his fellowship at Northwestern Hospital.
ABK Biomedical Inc. is pursuing validation, production and sale of OccluSystem, ABK's lead radiopaque embolic product, as it develops additional therapies for chemoembolization and radioembolization. While still investigational, ABK’s innovative radiopaque embolic therapies have the potential to provide simpler, safer and more cost effective solutions for treating hypervascular tumors and diseases.
